• Men and women aged 18-55 at the time of screening visit;

• Body mass index (BMI) 18.5-28 kg/m2, inclusive, and total body weight ≥50 kg for male or ≥45 kg for female;

• Voluntarily participate in the study and provide the signed and dated informed consent;

• For female subjects:

‣ With no childbearing potential, including those who has surgical sterilization (documented tubal ligation, hysterectomy, or bilateral oophorectomy) at least 6 weeks before the screening visit, and who menopause ≥12 months before the screening visit (confirmed by a follicle stimulating hormone (FSH) level ≥40IU/L), or

⁃ With childbearing potential (WOCBP), must not be pregnant nor lactating, and must have used nonpharmacologic contraception 30 days before administration, during the study, and for 3 months after dose, and must have tested negative for human chorionic gonadotropin (hCG) at the screening visit and D-1; female subjects must refrain from egg donation during this period.

• Males who are sexually active with WOCBP must have used nonpharmacologic contraception 14 days before administration, during the study, and for 3 months after administration. Male subjects must refrain from sperm donation during this time.

• Subject is willing to comply with protocol-specified visits, treatments, laboratory tests, and other study-related procedures and requirements.

• Men and women aged 18-70 at the time of screening visit;

• Body mass index (BMI) 18-35 kg/m2, inclusive, and total body weight ≥ 40 kg;

• Patients with plaque psoriasis who meet the following criteria during screening:

‣ Diagnosis of plaque psoriasis for at least 6 months before the first administration, and, in the opinion of the Investigator, have stable psoriasis with no significant progression or morphological changes.

⁃ Psoriasis Area and Severity Index (PASI) score 12

⁃ Static physician's global assessment (sPGA) ≥3

⁃ Psoriatic plaques must cover 10% of body surface area (BSA)

⁃ Deemed by Investigator to be eligible for phototherapy or systemic therapy

⁃ Subject is willing to discontinue topical and/or systemic therapies other than the investigational drugs, with the exception of topical moisturizer and low-intensity topical steroids used for salvage therapy.

• Voluntarily participate in the study and provide the signed and dated informed consent；

• For female subjects:

‣ With no childbearing potential, including those who has surgical sterilization (documented tubal ligation, hysterectomy, or bilateral oophorectomy) at least 6 weeks before the screening visit, and who menopause ≥12 months before the screening visit (confirmed by a follicle stimulating hormone (FSH) level ≥40IU/L), or

⁃ With childbearing potential (WOCBP), must not be pregnant nor lactating, and must have used nonpharmacologic contraception 30 days before administration, during the study, and for 3 months after dose, and must have tested negative for human chorionic gonadotropin (hCG) at the screening visit and D-1; female subjects must refrain from egg donation during this period;

• Males who are sexually active with WOCBP must have used nonpharmacologic contraception 14 days before administration, during the study, and for 3 months after administration. Male subjects must refrain from sperm donation during this time;

• Subject is willing to comply with protocol-specified visits, treatments, laboratory tests, and other study-related procedures and requirements.